

Listing of the Claims:

The following is a complete listing of all the claims in the application, with an indication of the status of each:

1-9. (Canceled)

10. (Currently amended) A therapeutical composition for the treatment of allergic disorders containing dendritic cells (DC) and/or lymphocytes cocultivated with said DC, wherein said DC have acquired the property to drive a T helper cell type I response, obtainable by a method comprising the step of culturing the DC from any source in the presence of at least one interferon (IFN) gamma or a variant thereof capable of binding to an IFN gamma receptor agonist and of at least one toll like receptor (TLR) 2 and TLR 6 agonist wherein ~~whereby~~ said TLR 2 and TLR 6 agonist is a bisacyloxypropyl-S-cystein derivative having a biological activity of macrophage activating lipopeptide 2 (MALP-2) to act as said TLR2 and TLR6 agonist.

11-24. (Canceled)

25. (Currently amended) The therapeutical composition according to claim 10 whereby said bisacyloxypropyl-S-cystein derivative is a lipopeptide derived from Mycoplasma fermentans ~~Mycoplasma fermentans~~ or a corresponding synthetic lipopeptide capable of stimulating macrophages in vitro or in vivo.

26. (Previously presented) The therapeutical composition according to claim 10 whereby said bisacyloxypropyl-S-cystein derivative is a macrophage activating lipopeptide 2kDa (MALP-2) or a biologically active derivative thereof.

27. (Currently amended) The therapeutical composition according to claim 10 ~~26~~ whereby said bisacyloxypropyl-S-cystein derivative is S-[2,3-bis(palmitoyloxy)-(2S)-propyl-L-cysteinyl-carboxy-polyehtyleneglycol or S-[2,3-bis(palmitoyloxy)-(2R)-propyl-L-cysteinyl-carboxy-polyehtyleneglycol .

28-29. (Canceled)

30. (Previously presented) The therapeutical composition according to claim 10 comprising the step of washing the treated DC and resuspending said DC in water, saline or a physiological medium.

31. (Previously presented) The therapeutical composition according to claim 10 wherein the DC are loaded with antigens.

32. (Currently amended) The therapeutical composition according to claim 10 wherein the lymphocytes for coculturing ~~cuculturing~~ the DC are autologous or allogenic ~~allergenic~~ lymphocytes acquired from the peripheral blood of donors whereafter the DC and the lymphocytes and optionally[,] further ingredients are cocultivated for a time period of ~~up to several days, preferably~~ at least 24 hours ~~and more preferred at least 3 days.~~

33-38. (Canceled)